-
Product Insights
Hyperoxaluria – Drugs In Development, 2023
Global Markets Direct’s, ‘Hyperoxaluria - Drugs In Development, 2023’, provides an overview of the Hyperoxaluria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Wilson Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Wilson Disease - Drugs In Development, 2023’, provides an overview of the Wilson Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Wilson Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Cholestasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cholestasis - Drugs In Development, 2023’, provides an overview of the Cholestasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cholestasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Progressive Familial Intrahepatic Cholestasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Progressive Familial Intrahepatic Cholestasis - Drugs In Development, 2023’, provides an overview of the Progressive Familial Intrahepatic Cholestasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Progressive Familial Intrahepatic Cholestasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VTX-801 in Wilson Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VTX-801 in Wilson Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VTX-801 in Wilson Disease Drug Details: VTX-801 is under development for the...
-
Product Insights
Wilson Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, and other tissues. Symptoms include abdominal pain, jaundice, problems with speech and swallowing, and muscle stiffness. Treatment includes chelators and Vitamin E supplements. The Wilson disease pipeline market research report provides comprehensive information on the therapeutics under development for Wilson disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – VTX-801
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry VTX-801 Drug Details VTX-801 is under development for the treatment of Wilson disease. The...
-
Analyst Opinions
Engineering Microorganisms into Powerful Micromachines: Can Synthetic Biology Foster Bio-Revolution?​
Achieving global goals such as mass-scale food production and sustainable low-cost manufacturing methods is the need of the hour. Synthetic Biology (SynBio) is a field of science that has grown over the last two decades to emerge as a mature area in biological engineering with its potential to reduce the costs of biological production methods and improve the global food supply. It also can be crucial to create patient-centric drugs and promote precision medicine for better health outcomes. SynBio is...
-
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...